Hereditary predisposition to cancer associated with the RAD51D gene is due to heterozygous pathogenic variants that reduce DNA repair by homologous recombination. It follows an autosomal dominant pattern and primarily increases the risk of epithelial ovarian, fallopian tube, or primary peritoneal cancer and, to a lesser extent, breast cancer. Penetrance is incomplete and loss of function favors genomic instability and tumor transformation.
Hereditary cancer (RAD51D gene)
The RAD51D gene encodes the RAD51D protein, one of the RAD51 recombinase paralogs and a component of the BCDX2 complex along with RAD51B, RAD51C, and XRCC2. This complex acts in the BRCA1 and BRCA2-dependent pathway, facilitating the formation and stability of RAD51 filaments, faithful repair of double-strand DNA breaks, and response to replication stress.
When one copy of RAD51D loses its function, the cell's ability to repair DNA without introducing errors decreases. In the tumor, the healthy copy can be inactivated, leading to homologous recombination deficiency, although this phenomenon is not present in all associated cancers. The average cumulative risk up to age 80 is estimated to be around 13% for tubo-ovarian cancer and 20% for breast cancer, but it can be higher or lower depending on family history, polygenic risk, and other factors. Pathogenic variants are infrequent, with an approximate prevalence of 0.05% in large cohorts of unaffected controls.
Symptoms
Carriers do not present clinical manifestations before developing a tumor. Ovarian, fallopian tube, or primary peritoneal cancer usually appears in adulthood and the risk mainly increases after 50 years of age; it can cause abdominal distension or pain, early satiety, urinary changes, intestinal alterations, or weight loss. Breast cancer also usually appears in adulthood and there is a higher proportion of estrogen receptor-negative and triple-negative tumors. The age of onset and progression are variable, and many carriers never develop cancer. No clinically actionable associations with other tumor types have been established.
Disease management
There is no treatment that eliminates genetic predisposition. Management is based on genetic counseling, individual risk estimation, and prevention or early detection. CA125 and transvaginal ultrasound do not reliably detect ovarian cancer in early stages, nor have they been shown to reduce mortality. Therefore, it is recommended to discuss a risk-reducing bilateral salpingo-oophorectomy around 45-50 years of age, after completing childbearing desires, or earlier if there is a family history of earlier onset. Delayed salpingectomy with oophorectomy is not considered an established alternative outside of clinical trials. Breast surveillance should be adapted to the calculated risk and usually includes annual mammography from approximately 40 years of age, incorporating magnetic resonance imaging when individual risk is high. Prophylactic mastectomy is not routinely indicated. Tumors are treated according to their location and molecular profile; homologous recombination deficiency may influence the use of platinums or PARP inhibitors, but an isolated germline variant does not guarantee therapeutic sensitivity.
Genes analyzed
Bibliography
eviQ Cancer Genetics Reference Committee. RAD51C or RAD51D - risk management (female). Cancer Institute NSW. 2026.
Yang X, Song H, Leslie G, et al. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. J Natl Cancer Inst. 2020;112(12):1242-1250.
Ngeow J, Chiang J, Astiazaran-Symonds E, et al. Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics. Genet Med. 2025;27(11):101557.
Torres-Esquius S, Llop-Guevara A, Gutiérrez-Enríquez S, et al. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer. JAMA Netw Open. 2024;7(4):e247811.
